Cencora, Inc. $COR Shares Sold by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ cut its stake in shares of Cencora, Inc. (NYSE:COR) by 17.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 308,510 shares of the company’s stock after selling 65,879 shares during the period. Skandinaviska Enskilda Banken AB publ owned approximately 0.16% of Cencora worth $92,507,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Atlantic Edge Private Wealth Management LLC raised its holdings in Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after buying an additional 35 shares during the period. Grove Bank & Trust raised its holdings in shares of Cencora by 4.3% during the second quarter. Grove Bank & Trust now owns 879 shares of the company’s stock valued at $264,000 after acquiring an additional 36 shares during the period. Quadcap Wealth Management LLC raised its holdings in shares of Cencora by 1.5% during the second quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock valued at $722,000 after acquiring an additional 36 shares during the period. U.S. Capital Wealth Advisors LLC boosted its stake in Cencora by 0.4% in the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company’s stock worth $2,563,000 after purchasing an additional 38 shares during the period. Finally, Monument Capital Management boosted its stake in Cencora by 2.4% in the 2nd quarter. Monument Capital Management now owns 1,637 shares of the company’s stock worth $491,000 after purchasing an additional 38 shares during the period. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Cencora

In related news, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total value of $1,868,397.44. Following the completion of the sale, the chief executive officer owned 65,746 shares of the company’s stock, valued at approximately $24,105,113.44. The trade was a 7.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 46,640 shares of company stock valued at $14,099,338 over the last three months. Insiders own 10.80% of the company’s stock.

Wall Street Analysts Forecast Growth

COR has been the topic of several recent analyst reports. Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Mizuho lifted their price target on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Wells Fargo & Company upped their price target on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Evercore ISI set a $400.00 price objective on Cencora and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Finally, TD Cowen lifted their target price on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $371.09.

Cencora Stock Performance

Shares of COR stock opened at $368.64 on Friday. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $377.54. The stock’s 50-day moving average is $334.14 and its two-hundred day moving average is $306.81. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The firm has a market cap of $71.47 billion, a P/E ratio of 37.93, a PEG ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.05. The business had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm’s revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the company earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date is Friday, November 14th. Cencora’s dividend payout ratio is presently 30.19%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.